摘要
目的观察左西孟旦联合托伐普坦治疗急性心力衰竭(AHF)合并低钠血症患者的临床效果。方法选择2017年1月至2020年1月入住我院的AHF合并低钠血症患者98例为研究对象,采用随机数字法分为观察组和对照组,每组49例。对照组患者给予左西孟旦治疗,观察组患者给予左西孟旦联合托伐普坦治疗。治疗7 d后,比较两组患者的治疗有效率、6 min步行距离;比较两组患者治疗前及治疗7 d后的左室射血分数(LVEF)、每搏输出量(SV)、心脏指数(CI)、24 h尿量、血钠水平;比较两组患者治疗期间的不良反应发生情况。结果治疗7 d,观察组患者的治疗总有效率(95.92%)显著高于对照组(77.55%),临床疗效明显优于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者的LVEF、SV、CI水平比较,差异均无统计学意义(P>0.05);治疗7 d后,两组患者LVEF、SV、CI水平均显著升高,观察组患者的水平显著高于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者24 h尿量、血钠水平比较,差异无统计学意义(P>0.05);治疗7 d后,两组患者的24 h尿量、血钠水平均显著升高,观察组患者的水平显著高于对照组;观察组患者的6 min步行距离明显远于对照组,差异有统计学意义(P<0.05)。治疗过程中,两组患者的不良反应发生率比较,差异无统计学意义(P>0.05)。结论左西孟旦联合托伐普坦治疗可有效缓解急性心力衰竭合并低钠血症患者的临床症状,改善心功能,增加排尿量,提高血钠水平,增强运动耐量,治疗安全性高。
Objective To observe the clinical effects of levosimendan injection combined with tolvaptan in the treatment of patients with acute heart failure(AHF)complicated with hyponatremia.Methods A total of 98 AHF patients complicated with hyponatremia hospitalized in our hospital from January 2017 to January 2020 were selected as the research objects.They were divided into observation group and control group by the random number method,with 49 cases in each group.Patients in the control group were treated with levosimendan injection,whereas the observation group was treated with levosimendan injection combined with tolvaptan for treatment.After 7 days of treatment,the effective rate and 6-minute walking distance were compared between the two groups.The left ventricular ejection fraction(LVEF),stroke volume(SV),and cardiac index(CI),24h urinary output,blood sodium levels of the two groups before and after 7 days of treatment were compared.The occurrence of adverse reactions between the two groups during the treatment was compared.Results After 7 days of treatment,patients in the observation group obtained a higher total effective rate(95.92%vs.77.55%),and superior clinical efficacy as compared with the control group,with statistically significant differences(P<0.05).Before treatment,there were no statistically significant differences in the levels of LVEF,SV,and CI between the two groups(P>0.05).After 7 days of treatment,the levels of LVEF,SV,and CI of the two groups significantly increased,and the observation group yielded higher levels in comparison with the control group,with statistically significant differences(P<0.05).Before treatment,there were no statistically significant differences in 24h urinary output and blood sodium level between the two groups(P>0.05).After 7 days of treatment,the 24h urinary output and blood sodium level of the two groups significantly increased,and the observation group yielded higher levels in comparison with the control group,and the 6-minute walking distance of the observation group w
作者
杨启岭
段卡丹
邱梅红
YANG Qiling;DUAN Kadan;QIU Meihong(Department of Cardiology,Luoyang Central Hospital Affiliated to Zhengzhou University,Luoyang 471000,Henan Province,China)
出处
《内科》
2021年第5期622-625,共4页
Internal Medicine
关键词
托伐普坦
左西孟旦
急性心力衰竭
低钠血症
Tolvaptan
Levosimendan injection
Acute heart failure
Hyponatremia
